A signature inferred from Drosophila mitotic genes predicts survival of breast cancer patients.

Competing Interests: The authors declare that they have deposited a patent application covering the commercial use of the DM signature as a prognostic tool for breast cancer. Funding: The financial support of the “Associazione Italiana per la Ricerca sul Cancro” (AIRC) to M.G. and P.P. and of the FIRB-Italbionet program to F.D.C. and P.P. are gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.